Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 (original) (raw)
Cervical cancer is the possible outcome of genital infection with highrisk human papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during which the host immune system fails to eliminate the virus. Fortunately, the majority of genital HPV infections are cleared before the development of (pre)malignant lesions. Analysis of CD4؉ T-helper (Th) immunity against the E2, E6, and E7 antigens of HPV16 in healthy women revealed strong proliferative E2-and E6-specific responses associated with prominent IFN-␥ and interleukin 5 secretion. This indicates that the naturally arising virus-induced immune response displays a mixed Th1/Th2 cytokine profile. Of all HPV16؉ cervical cancer patients, approximately half failed to mount a detectable immune response against the HPV16-derived peptides.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.